Loading...
NPI 1235600214 · Mckinney, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Sval is a clinical medical laboratory provider located in Mckinney, Texas. This profile covers 4 Medicare and 39 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Sval |
| Address | 3900 S Stonebridge Dr Ste 801 |
| City | Mckinney |
| State | TX |
| ZIP | 75070 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 17, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $27.7M |
| Medicaid | $34.9K |
SVAL is a Clinical Medical Laboratory NPI enumerated 2018-12-17 (~8 years ago) and shows a billing profile dominated by COVID-era testing codes, indicating rapid scaling of testing-related operations since enrollment. The taxonomy and code mix point to a laboratory that offers both high-volume test provisioning and traditional lab services rather than a general ambulatory practice.
Medicare revenue is concentrated almost entirely in a very small set of codes: the provider reports $27.7M total Medicare revenue and the precomputed top 3 Medicare codes account for 100.0% of that revenue. K1034 alone is listed at $27.9M and 98.5% of Medicare revenue, signaling a near-monolithic dependence on that single Medicare code for topline receipts.
K1034 is a national outlier for this provider on Medicare: K1034 ranks #8 of 30143 providers nationally (100th percentile; extreme outlier). That placement indicates SVAL is operating at an unusually large national volume for the nonprescription self-administered COVID-19 test provision described by K1034, while its other Medicare lab codes (G0483 and 80307) contribute only a small share of revenue.
Although SVAL bills multiple lab services, the Medicare mix shows a secondary service line in definitive drug testing and screening (G0483 $339.5K, 80307 $80.8K), which together represent a small fraction of Medicare revenue compared with K1034. Those drug-testing codes rank in higher percentiles but are described as typical, unremarkable volumes for their peer groups, suggesting these are established but modest revenue streams relative to the K1034 activity.
On Medicaid the provider’s scale is much smaller: total Medicaid revenue is $34.9K versus $27.7M in Medicare, meaning SVAL is effectively Medicare-dominant in the dataset. The Medicaid top three codes (U0003, K1034, G2023) together account for 72.2% of the provider’s Medicaid revenue, showing a concentrated Medicaid footprint that nevertheless is tiny relative to its Medicare business.
The Medicaid code-level mix shows a split between high-throughput molecular testing and specimen collection plus K1034 distribution: U0003 is $11.8K (33.7% of Medicaid revenue), K1034 is $7.3K (21.0%), and G2023 is $6.1K (17.5%). K1034 is again an extreme state-level outlier for Medicaid (rank #2 of 77 in-state, 99th percentile), while U0003 (rank #158 of 337, 53th percentile) and G2023 (rank #85 of 335, 75th percentile) are characterized as typical, unremarkable volumes in their peer groups.
Several Medicaid-listed procedure codes show claims counts but report $0 avg paid/claim (for example, 87651, 87591, 87653 and many molecular/genetic codes), which indicates that although services were recorded in the claim stream, there is no registered Medicaid reimbursement for those codes in this dataset. This pattern can reflect reporting, bundling, or coverage/payment differences and is important for analysts reconciling service volume with recorded Medicaid payments.
Taken together, SVAL’s profile is that of a laboratory-scale operation that became heavily concentrated in COVID test provisioning and related specimen/processing activity: nationally dominant in the Medicare K1034 channel and a pronounced state-level outlier on the same code for Medicaid, while other lab service lines (definitive drug testing, presumptive drug screens, high-throughput PCR testing) exist at modest, more typical volumes. The tenure since 2018-12-17 (~8 years) suggests the organization achieved this concentrated scale quickly, largely through pandemic-era testing demand.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 2,323,120 | $10 | $27.9M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,400 | $240 | $339.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,330 | $60 | $80.8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 30 | $150 | $4.7K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 4 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
39 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 510 | $20 | $11.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 7,320 | $1 | $7.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1,020 | $10 | $6.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 510 | $10 | $3.6K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 450 | $10 | $2.2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,040 | $1 | $2K |
| 86328 | The lab analyst performs a single–step immunoassay to qualitatively or semiquantitatively evaluate the patient’s specimen for antibodies to the severe acute respiratory syndrome coronavirus 2… | 90 | $10 | $950 |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 40 | $20 | $920 |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,050 | $0 | $0 |
| 81225 | The lab analyst performs the technical lab test to detect the presence of common changes in the gene for cytochrome P450, family 2, subfamily C, polypeptide 19, also known as CYP2C19. | 50 | $0 | $0 |
Showing 1–10 of 39
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
39 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 158 | 340 | 400 | $50 | $553.5K |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 27 | 40 | 100 | $230 | $335.3K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 138 | 240 | 420 | $30 | $296.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 154 | 290 | 410 | $20 | $225K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 157 | 300 | 410 | $20 | $223.4K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 75 | 110 | 360 | $40 | $174.9K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 23 | 100 | 650 | $50 | $161.3K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 140 | 260 | 640 | $20 | $137.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 36 | 70 | 200 | $50 | $124.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 73 | 350 | 510 | $30 | $114.1K |
Showing 1–10 of 39
Other providers in the same ZIP code as Sval, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Aunt Mae's Home Care | TX | Home Health Agency | $0 | $21.7M |
| Children's Health Pm Urgent Care, PLLC | TX | Urgent Care Clinic/Center | $0 | $13.5M |
| Sara Rosado | TX | Physician Assistant | $2.2M | $0 |
| Osama Abdul-rahim | TX | Vascular & Interventional Radiology Physician | $1.5M | $0 |
| Charles Toulson | TX | Orthopaedic Surgery Physician | $591K | $0 |
| Synaptixs Ionm, LLC | TX | Physiological Laboratory | $420.2K | $0 |
| Dale Yoo | TX | Clinical Cardiac Electrophysiology Physician | $330.7K | $0 |
| Wilson Creek Surgical Center, LLC | TX | Ambulatory Surgical Clinic/Center | $204.2K | $0 |
| Texas Health Craig Ranch Surgery Center LLC | TX | Ambulatory Surgical Clinic/Center | $172.7K | $0 |
| Joby James | TX | Internal Medicine Physician | $166.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.